Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron, Sutent, and Tarceva in Metastatic RCC
NCT00522249Phase 2Terminated
- Sponsor
- Houston Methodist Research Institute
- Start
- May 2007
- Primary completion
- May 2008
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b, sunitinib, erlotinib in metastatic renal cell carcinoma (mRCC), sponsored by Houston Methodist Research Institute. Started May 2007; status: terminated.
02
Drugs
peginterferon alfa-2bsunitiniberlotinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT00522249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522249.